• Who we are
Multispecific yet truly natural antibodies

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Who we are
Who we are

Long term pharma and biotech professionals with a track record of leading projects from research into the market

Our antibody development roots go deep

Our focus
Our focus

Multispecific yet natural

Alzheimer’s Disease and Antimicrobial Resistance

CD47 Dual targeting
Our pipeline

Fully human bi- and multi-specific antibodies for the treatment of Alzheimer’s Disease and Antimicrobial Resistant infections

Safe and selective blockade of CD47 on tumors

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow

Oliver Eckelmann, CEO

Oliver is a co-founder of the discoveric bio group and serves as the CEO.

Before commencing in the field of Biotech entrepreneurship, he joined the Pharmaceutical company Roche in the beginning of 2006 and has held positions of increasing responsibility in controlling and planning. In 2009 he was appointed as Roche’s VP/Global Head of Strategy, Planning and Special Projects in Basel, Switzerland. In September 2012 he took over the role as CFO and Deputy CEO for Roche in Australia.

At the beginning of his career, he has held positions with consultancy firms Booz & company and Roland Berger Strategy Consultants.

Oliver holds a PhD in economics.

Oliver Eckelmann

Back